RxDoctor Payments DataLook up a doctor →

Brooke Faught, NP

Nurse Practitioner · Nashville, TNNPI 1255316238

Payments from drug & device makers

$89,450in general payments, 2019–2025

Across 439 payments — averaging $203.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$37K
  • Agile Therapeutics, Inc.$25K
  • Mayne Pharma Commercial LLC$8K
  • Acella Pharmaceuticals, LLC$8K
  • Ipsen Innovation$3K
  • Bayer$2K
  • plus $6K from 31 others

What the payments were for

  • Consulting fees$9,79011%
  • Speaking & faculty fees$61,20270%
  • Travel & lodging$8,1149%
  • Food & beverage$7,0538%
  • Education$7141%
  • Gifts$200%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,450 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,645
Medicare patients
40
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron18$14,809
BijuvaEstradiol/Progesterone30$12,243
OsphenaOspemifene12$7,522
Estradiol (Twice Weekly)Estradiol19$1,884
Estradiol34$1,749
ProgesteroneProgesterone, Micronized29$1,640
SynthroidLevothyroxine Sodium17$1,629
Terconazole15$870
Nystatin11$483
Fluconazole63$472
NitrofurantoinNitrofurantoin Macrocrystal14$402
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$392
Montelukast Sodium15$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$37,410$14,80918 claims
Therapeuticsmd, Inc.Bijuva$251$12,24330 claims
AbbVieSynthroid$331$1,62917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →